Use of two ppap compounds in the preparation of a medicament for treating neurodegenerative diseases

By extracting and purifying hyphenrone A and hyphenrone L from St. John's wort in Kangding, a pharmaceutical composition was prepared, which solved the problem of the lack of voltage-gated T-type calcium channel enhancers in the prior art and achieved effective treatment for neurodegenerative diseases.

CN120732843BActive Publication Date: 2026-06-09KUNMING INST OF BOTANY CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Patent Type
Patents(China)
Current Assignee / Owner
KUNMING INST OF BOTANY CHINESE ACAD OF SCI
Filing Date
2025-07-15
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

There are no reports in the existing technology of hypophenrone A and hypophenrone L enhancing the activity of voltage-gated T-type calcium channels, nor are there any reports of their application in the preparation of drugs for the treatment of cerebellar spinal cord ataxia, Alzheimer's disease and intellectual disability syndrome.

Method used

The polycyclic isopentenyl yl phloroglucinols, hypophenrone A and hypophenrone L, isolated from St. John's wort in Kangding, were prepared into a pharmaceutical composition by methanol extraction, silica gel column chromatography and HPLC purification. This composition enhances the activity of voltage-gated T-type calcium channels and can be used to prepare drugs for the treatment of neurodegenerative diseases.

Benefits of technology

Compounds hypophenrone A and hypophenrone L significantly enhance the current of T-type voltage-gated calcium channels, and can be used to prepare drugs for the relief and treatment of spinocerebellar ataxia, Alzheimer's disease and cognitive impairment syndrome, which have potential clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120732843B_ABST
    Figure CN120732843B_ABST
Patent Text Reader

Abstract

The application provides application of polycyclic polyisoprenyl acyl phloroglucinol compounds (PPAP) of two different skeleton types in preparation of medicines for relieving / treating neurodegenerative diseases. The application belongs to the technical field of medicines. The hyphenrone A provided by the application is a 1,9-cracked polycyclic polyisoprenyl acyl phloroglucinol compound, and the hyphenrone L is a polycyclic polyisoprenyl acyl phloroglucinol compound with a complex ring system formed by intramolecular [4+2] cyclization of a monocyclic polyisoprenyl acyl phloroglucinol compound. The compound hyphenrone A and the compound hyphenrone L both have the activity of enhancing the voltage-gated T-type calcium channel current, and can be used for preparing medicines for treating neurodegenerative diseases, and in particular, can be used for preparing medicines for relieving and / or treating diseases such as spinocerebellar ataxia, Alzheimer's disease and mental retardation syndrome, and have the clinical application value.
Need to check novelty before this filing date? Find Prior Art